<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274311</url>
  </required_header>
  <id_info>
    <org_study_id>ClomipheneAcro</org_study_id>
    <nct_id>NCT02274311</nct_id>
  </id_info>
  <brief_title>Clomiphene Citrate for Treatment of Acromegaly</brief_title>
  <official_title>Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Felipe Henning Gaia Duarte</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of clomiphene citrate on serum insulin like growth factor 1 and
      testosterone levels in male acromegalic patients not controlled by surgery, radiotherapy
      and/or medical treatments (somatostatin analogues, dopamine agonists and/or growth hormone
      receptor antagonist)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acromegaly, a disease caused by a growth hormone secreting pituitary adenoma, results in
      reduced life span. Despite the many modalities available to treat this disease,as surgery,
      medical treatment and radiotherapy, uncontrolled disease persists in a significant portion of
      patients

      Oral estrogens, alone or in combination with somatostatin receptor analogues, have been shown
      to control acromegaly in women. Selective estrogen receptor modulators (SERMs) resulted in
      similar effects in both genders. Clomiphene citrate, a SERM that increases luteinizing
      hormone and follicle stimulating hormone secretion, improves hypogonadism and fertility
      outcomes.

      The aim of this study is to assess the impact of clomiphene citrate on serum insulin like
      growth factor 1 and testosterone levels in male acromegalic patients not controlled by
      surgery, radiotherapy and/or medical treatment.

      In this prospective, open label, single center trial, sixteen male patients were studied.
      Clomiphene citrate (50 mg/day) was added to previous medical treatment for 3 months and
      hormonal assessment was performed prior to and during the intervention. Hormones included:
      growth hormone, insulin like growth factor, total testosterone, follicle stimulating hormone,
      luteinizing hormone and prostate-specific antigen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGF-1 Levels</measure>
    <time_frame>Day 90</time_frame>
    <description>The objective is to compare the change of IGF-1 value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testosterone Levels</measure>
    <time_frame>D90</time_frame>
    <description>The objective is to compare the change of testosterone value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Levels</measure>
    <time_frame>Day 90</time_frame>
    <description>The objective is to compare the change of PSA value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Clomiphene citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving clomiphene citrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>Clomiphene citrate, 50 mg, orally for three months</description>
    <arm_group_label>Clomiphene citrate</arm_group_label>
    <other_name>Clomid; Serophene; Indux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with active acromegaly on regular use of a stable dose of Octreotide-LAR
             and/or cabergoline for at least one year,

          -  Insulin like growth factor 1 above the reference range during the last year of
             follow-up and

          -  testosterone levels within or below the third inferior tertile of normality.

        Exclusion Criteria:

          -  radiotherapy in the last 10 years, previous venous embolism (including family
             members),

          -  previous prostatic cancer or symptomatic benign hypertrophy,

          -  triglyceride levels above 400 mg/dL,

          -  renal failure defined by estimative of renal filtration below 30 ml/min,

          -  liver disease defined by hepatic enzymes 3 times above normal limit,

          -  active oncologic disease in the last 10 years and previous cardiac or cerebrovascular
             disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcello D Bronstein, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Neuroendocrinology, Discipline of Endocrinology, Department of Internal Medicine Clinical Hospital of the University of São Paulo Medical School, São Paulo, Brazil</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <results_first_submitted>December 1, 2015</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Felipe Henning Gaia Duarte</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>SERM</keyword>
  <keyword>Clomiphene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Acromegalic patients with uncontrolled hormonal levels despite current medical treatment</recruitment_details>
      <pre_assignment_details>Patients should be on stable medical treatment for at least 6 months prior entering the study. Patients submitted to radiotherapy in the last 10 years were not eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clomiphene Citrate</title>
          <description>Patients receiving clomiphene citrate
Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months
16 patients were enrolled</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Three Months of Clomiphene Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Three Months of Clomiphene Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clomiphene Citrate</title>
          <description>Patients receiving clomiphene citrate Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months
Patients with active acromegaly, defined by high IGF-1 levels, on regular use of a stable dose of Octreotide-LAR and/or Cabergoline for at least 1 year; IGF-1 above the reference range during the last year of follow-up; and T levels within or below the third inferior tertile of normality.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" lower_limit="36" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Only male patients were recruited</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IGF-1 Levels</title>
        <description>The objective is to compare the change of IGF-1 value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
        <time_frame>Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene Citrate</title>
            <description>Patients receiving clomiphene citrate
Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months
16 patients were enrolled.
IGF-1 values were assessed at D0 (baseline) and D90 (mean values)</description>
          </group>
        </group_list>
        <measure>
          <title>IGF-1 Levels</title>
          <description>The objective is to compare the change of IGF-1 value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Measures of central tendency (mean) and variability (range and/or SD) were used to describe numeric variables. Paired Student’s t test was used to verify the mean differences between dependent normally distributed variables. Wilcoxon sign test was performed to non-normally distributed dependent variables.
Asignificance level of 5%was adopted for all statistical tests (P &lt;.05).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone Levels</title>
        <description>The objective is to compare the change of testosterone value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
        <time_frame>D90</time_frame>
        <population>10 acromegalic patients were assessed, the other 6 patients did not have testosterone levels assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene Citrate</title>
            <description>Patients receiving clomiphene citrate Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months 16 patients were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Levels</title>
          <description>The objective is to compare the change of testosterone value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
          <population>10 acromegalic patients were assessed, the other 6 patients did not have testosterone levels assessed.</population>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Levels</title>
        <description>The objective is to compare the change of PSA value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
        <time_frame>Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clomiphene Citrate</title>
            <description>Patients receiving clomiphene citrate
Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months
16 patients were enrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Levels</title>
          <description>The objective is to compare the change of PSA value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90).</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected at D90 (3 months after the begging of the study)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clomiphene Citrate</title>
          <description>Patients receiving clomiphene citrate
Clomiphene Citrate: Clomiphene citrate, 50 mg, orally for three months
No adverse events were reported</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Felipe Henning Gaia Duarte</name_or_title>
      <organization>Hospital das Clinicas da Faculdade de Medicina da USP</organization>
      <phone>+5511987550990</phone>
      <email>drfelipegaia@outlook.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

